Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Free Report) – Analysts at HC Wainwright dropped their Q3 2026 EPS estimates for shares of Cullinan Therapeutics in a research report issued on Monday, August 10th. HC Wainwright analyst R. Burns now forecasts that the company will earn ($0.90) per share for the quarter, down from their prior estimate of ($0.87). HC Wainwright has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Cullinan Therapeutics’ current full-year earnings is ($3.01) per share. HC Wainwright also issued estimates for Cullinan Therapeutics’ Q4 2026 earnings at ($0.93) EPS, FY2026 earnings at ($3.53) EPS, Q1 2027 earnings at ($0.77) EPS, Q2 2027 earnings at ($0.78) EPS, Q3 2027 earnings at ($0.80) EPS, Q4 2027 earnings at ($0.82) EPS and FY2027 earnings at ($3.17) EPS.
Cullinan Therapeutics (NASDAQ:CGEM – Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.01).
Read Our Latest Report on CGEM
Cullinan Therapeutics Price Performance
CGEM opened at $19.63 on Wednesday. The firm has a market capitalization of $1.26 billion, a P/E ratio of -6.33 and a beta of 0.01. Cullinan Therapeutics has a one year low of $5.68 and a one year high of $19.82. The company has a fifty day moving average price of $16.72 and a 200-day moving average price of $14.94.
Insider Activity
In other news, insider Jennifer Michaelson sold 8,000 shares of Cullinan Therapeutics stock in a transaction on Monday, July 6th. The shares were sold at an average price of $17.82, for a total transaction of $142,560.00. Following the completion of the sale, the insider directly owned 162,844 shares of the company’s stock, valued at approximately $2,901,880.08. The trade was a 4.68% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 8.60% of the company’s stock.
Institutional Investors Weigh In On Cullinan Therapeutics
A number of large investors have recently added to or reduced their stakes in CGEM. BlackRock Inc. purchased a new position in shares of Cullinan Therapeutics in the 2nd quarter worth about $95,289,000. Affinity Asset Advisors LLC increased its position in shares of Cullinan Therapeutics by 632.4% during the 4th quarter. Affinity Asset Advisors LLC now owns 1,932,106 shares of the company’s stock valued at $19,997,000 after purchasing an additional 1,668,289 shares during the last quarter. Blue Owl Capital Holdings LP purchased a new position in shares of Cullinan Therapeutics during the 2nd quarter valued at about $28,039,000. Lynx1 Capital Management LP raised its holdings in shares of Cullinan Therapeutics by 31.0% during the 3rd quarter. Lynx1 Capital Management LP now owns 5,766,090 shares of the company’s stock valued at $34,193,000 after buying an additional 1,365,248 shares in the last quarter. Finally, Boothbay Fund Management LLC bought a new stake in Cullinan Therapeutics in the 4th quarter worth approximately $12,803,000. Hedge funds and other institutional investors own 86.31% of the company’s stock.
Key Stories Impacting Cullinan Therapeutics
Here are the key news stories impacting Cullinan Therapeutics this week:
- Positive Sentiment: HC Wainwright reiterated its Buy rating and maintained a $30 price target, implying substantial upside from the stock’s recent level near $19.63. The bullish target appears to be supporting investor sentiment, particularly as the shares trade close to their 52-week high.
- Neutral Sentiment: HC Wainwright projects continued quarterly losses but expects estimated EPS of ($0.77), ($0.78), ($0.80) and ($0.82) for the first four quarters of 2027, respectively, resulting in a projected FY2027 loss of ($3.17) per share. These forecasts provide investors with a view of the company’s expected cash-burning phase but do not signal near-term profitability.
- Negative Sentiment: HC Wainwright lowered its Q3 2026 EPS estimate to ($0.90) from ($0.87), Q4 2026 to ($0.93) from ($0.90), and FY2026 to ($3.53) from ($3.42). The revisions indicate somewhat higher expected losses and could limit gains despite the favorable rating and price target.
- Neutral Sentiment: Reported short interest was listed at zero shares, unchanged from the prior period, with a zero-day days-to-cover ratio. Because the figures appear incomplete or anomalous, they offer little actionable information about trading pressure.
About Cullinan Therapeutics
Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.
Featured Stories
- Five stocks we like better than Cullinan Therapeutics
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for Cullinan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cullinan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
